General literature
Open resources for chemical probes and their implications for future drug discovery

Balıkçı E., Marques A. M. C., Hansen J. S., Huber K. V. M.

Expert Opin Drug Discov. 2023, 18(5):505-513. open access

DOI
PubMed
Success examples
AMPK activation protects against prostate cancer by inducing a catabolic cellular state

Penfold L., Woods A., Pollard A. E., Arizanova J., Pascual-Navarro E., Muckett P. J., Dore M. H., Montoya A., Whilding C., Fets L., Mokochinski J., Constantin T. A., Varela-Carver A., Leach D. A., Bevan C. L., Nikitin A. Y., Hall Z., Carling D.

Cell Rep. 2023, 42(4):112396.

AMPK Activator
DOI
PubMed
Success examples
Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors

Malone C. F., Kim M., Alexe G., Engel K., Forman A. B., Robichaud A., Saur Conway A., Goodale A., Meyer A., Khalid D., Thayakumar A., Hatcher J. M., Gray N. S., Piccioni F., Stegmaier K.

Cancer Res 2023, 83(2):285-300.

CDK8 inhibitor
DOI
PubMed
General literature
The era of high-quality chemical probes

Licciardello M. P., Workman P.

Med Chem. 2022, 13(12):1446-1459. open access

DOI
PubMed
Success examples
Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders

Hanzl A., Casement R., Imrichova H., Hughes S. J., Barone E., Testa A., Bauer S., Wright J., Brand M., Ciulli A., Winter G. E.

Nat Chem Biol 2022, 61(2):599-618.

SMARCA2/4 PROTAC
DOI
PubMed
Success examples
Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket

Wallon L., Khan I., Teng K. W., Koide A., Zuberi M., Li J., Ketavarapu G., Traaseth N. J., O'Bryan J. P., Koide S.

Proc Natl Acad Sci U S A 2022, 119(43):e2204481119.

KRAS switch I/II pocket inhibitor
DOI
PubMed